Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30267045 | 1.00 | GABRA1 (0.41) | GABRA1GABRB2ALDH1A1TSHRTAAR1 | |
| SCHEMBL2811529 | 0.85 | GABRA1 (0.42) | GABRA1GABRB2ALDH1A1TSHRTAAR1 | |
| SCHEMBL7322742 | 0.81 | GABRA1 (0.58) | GABRA1GABRB2ALDH1A1TSHRTAAR1 | |
| SCHEMBL608459 | 0.79 | TAAR1 (0.45) | GABRA1GABRB2ALDH1A1TSHRTAAR1 | |
| SCHEMBL31142838 | 0.79 | TAAR1 (0.45) | GABRA1GABRB2ALDH1A1TSHRTAAR1 | |
| SCHEMBL147988 | 0.79 | PDCD1 (0.53) | GABRA1GABRB2ALDH1A1TSHRTAAR1 | |
| SCHEMBL9860948 | 0.79 | GABRA1 (0.39) | GABRA1GABRB2ALDH1A1TSHRTAAR1 | |
| SCHEMBL21928918 | 0.79 | GABRA1 (0.39) | GABRA1GABRB2ALDH1A1TSHRTAAR1 | |
| SCHEMBL12856675 | 0.78 | — | — | |
| SCHEMBL1281831 | 0.78 | ESR1 (0.44) | GABRA1GABRB2ALDH1A1TSHRTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| US-20240374595-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-11-14 | — | — | US | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-12083118-B2 | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-09-10 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| US-20240246931-A1 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | Jubilant Prodel LLC (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-6586633-B1 | Antifungal agents | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6579884-B1 | Compounds | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| CN-1329613-A | novel compounds | ASTRAZENECA AB (SE) | 2002-01-02 | — | — | CN | disclosed |
| EP-1112998-A1 | AMINE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-1105391-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000011000-A2 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-02 | — | — | WO | disclosed |
| US-4417052-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; VIRICIDES | STERLING DRUG INC. (US) | 1983-11-22 | — | — | US | disclosed |
| US-4308382-A | ANTIINFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1981-12-29 | — | — | US | disclosed |
| US-4216326-A | Intermediates for preparing anti-inflammatory phenyl-lower-alkylamines | STERLING DRUG INC. (US) | 1980-08-05 | — | — | US | disclosed |
| US-4069256-A | Anti-inflammatory phenyl-lower-alkylamines | STERLING DRUG INC. (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083118-B2 | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same | HAVCR2, HMBS, BCL3 | GABRA1 1515/4885GABRB2 2122/4885ALDH1A1 1003/4885 |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | GABRA1 802/4885GABRB2 1105/4885ALDH1A1 3352/4885 |
| US-20240246931-A1 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | CD274, PDCD1, PDCD1LG2 | GABRA1 2122/4885GABRB2 3149/4885ALDH1A1 80/4885 |
| US-20240374595-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, CDV3 | GABRA1 1663/4885GABRB2 2285/4885ALDH1A1 777/4885 |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | GABRA1 2499/4885GABRB2 2590/4885ALDH1A1 3624/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | GABRA1 2499/4885GABRB2 2590/4885ALDH1A1 3624/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | GABRA1 2499/4885GABRB2 2590/4885ALDH1A1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.